drugset / Trial / NCT07540494

Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects

NCT07540494

Phase 1 Not yet recruiting 12 enrolled GH Research Ireland Limited
NaSingle-groupOpen-labelTreatment

Summary

The primary objectives of this trial are to determine the pharmacokinetic (PK) profile and the safety and tolerability of GH001 delivered via a proprietary aerosol delivery device in healthy subjects after single-dose administration.

Timeline

Start
2026-04
Primary completion
2026-05
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Mebufotenin Small molecule Inhaled

Indications

No indication recorded.